5.09
price up icon3.46%   0.17
after-market Dopo l'orario di chiusura: 5.11 0.02 +0.39%
loading
Precedente Chiudi:
$4.92
Aprire:
$4.93
Volume 24 ore:
1.69M
Relative Volume:
0.83
Capitalizzazione di mercato:
$386.22M
Reddito:
$823.60M
Utile/perdita netta:
$-116.00M
Rapporto P/E:
-3.9154
EPS:
-1.3
Flusso di cassa netto:
$-107.30M
1 W Prestazione:
+21.48%
1M Prestazione:
-29.99%
6M Prestazione:
-66.36%
1 anno Prestazione:
-77.17%
Intervallo 1D:
Value
$4.93
$5.17
Intervallo di 1 settimana:
Value
$4.17
$5.40
Portata 52W:
Value
$3.8119
$29.30

Myriad Genetics Inc Stock (MYGN) Company Profile

Name
Nome
Myriad Genetics Inc
Name
Telefono
801-584-3600
Name
Indirizzo
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Name
Dipendente
2,700
Name
Cinguettio
@myriadgenetics
Name
Prossima data di guadagno
2025-02-24
Name
Ultimi documenti SEC
Name
MYGN's Discussions on Twitter

Confronta MYGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Diagnostics & Research icon
MYGN
Myriad Genetics Inc
5.09 386.22M 823.60M -116.00M -107.30M -1.30
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
401.90 152.06B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
196.02 135.91B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
524.91 41.29B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
115.80 31.79B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
152.32 24.28B 15.50B 1.33B 2.16B 7.34

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-21 Downgrade Scotiabank Sector Outperform → Sector Perform
2025-05-08 Downgrade Wolfe Research Outperform → Peer Perform
2025-05-07 Downgrade Wells Fargo Overweight → Equal Weight
2025-04-09 Downgrade Guggenheim Buy → Neutral
2025-03-12 Aggiornamento Piper Sandler Neutral → Overweight
2025-02-12 Iniziato Craig Hallum Buy
2024-12-10 Iniziato UBS Neutral
2024-12-09 Downgrade Leerink Partners Outperform → Market Perform
2024-09-19 Iniziato Morgan Stanley Equal-Weight
2024-08-28 Iniziato Wells Fargo Overweight
2024-06-27 Iniziato Scotiabank Sector Outperform
2024-06-03 Ripresa Jefferies Underperform
2024-05-08 Aggiornamento Leerink Partners Market Perform → Outperform
2023-12-21 Ripresa Piper Sandler Neutral
2023-12-19 Iniziato Wells Fargo Equal Weight
2023-12-14 Iniziato Guggenheim Buy
2023-12-13 Iniziato Wolfe Research Outperform
2023-07-05 Ripresa JP Morgan Underweight
2023-05-23 Aggiornamento Goldman Sell → Buy
2023-01-18 Aggiornamento Raymond James Mkt Perform → Outperform
2022-10-06 Iniziato Stephens Equal-Weight
2021-10-15 Ripresa Cowen Market Perform
2021-06-15 Iniziato Raymond James Mkt Perform
2021-06-03 Iniziato Goldman Sell
2019-09-26 Downgrade BofA/Merrill Neutral → Underperform
2019-08-14 Downgrade Piper Jaffray Overweight → Neutral
2019-08-02 Aggiornamento BofA/Merrill Underperform → Neutral
2019-08-01 Aggiornamento Barclays Underweight → Equal Weight
2019-07-29 Downgrade Needham Strong Buy → Hold
2019-07-09 Downgrade Cowen Outperform → Market Perform
2019-03-12 Reiterato Needham Strong Buy
2019-01-03 Iniziato Needham Strong Buy
2018-11-30 Aggiornamento Goldman Sell → Neutral
2018-10-10 Aggiornamento Piper Jaffray Neutral → Overweight
2018-07-11 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2018-03-21 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2018-01-29 Iniziato Goldman Sell
2018-01-22 Reiterato Barclays Equal Weight
2018-01-05 Iniziato BTIG Research Buy
2017-10-02 Ripresa Leerink Partners Mkt Perform
2017-08-09 Reiterato Barclays Equal Weight
2017-02-08 Aggiornamento Ladenburg Thalmann Sell → Neutral
2017-01-18 Iniziato Deutsche Bank Sell
2016-10-10 Downgrade Ladenburg Thalmann Neutral → Sell
Mostra tutto

Myriad Genetics Inc Borsa (MYGN) Ultime notizie

pulisher
Jun 06, 2025

3 Reasons to Avoid MYGN and 1 Stock to Buy Instead - FinancialContent

Jun 06, 2025
pulisher
Jun 05, 2025

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 03, 2025

7-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline Tomorrow - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

Trend Tracker for (MYGN) - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

US Direct-To-Consumer Genetic Testing Market Report 2025, - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

US Direct-To-Consumer Genetic Testing Market Report 2025, Competitive Analysis of 23andMe, Gene by Gene, Ancestry, Genesis, EasyDNA, Veritas, Myriad Genetics, Taconic Biosciences, & Color Health - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

Myriad Genetics (MYGN) Launches FirstGene Multiple Prenatal Screen | MYGN Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Myriad Genetics Launches FirstGene™ Prenatal Screen for Comprehensive Genetic Risk Assessment in One Blood Draw - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

Breakthrough Prenatal Screen Combines 4 Tests in 1 Blood DrawNo Father Sample Needed - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

Hereditary Testing MarketGlobal Industry Trends, - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

MYGN INVESTOR REMINDER: Hagens Berman Reminds Myriad Genetics (MYGN) Investors of Securities Fraud Lawsuit, Encourages Investors Who Lost $50,000+ to Contact the Firm - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 02, 2025

Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Myriad Genetics Reports Ultra-Sensitive CtDNA Detection With Precise MRD In Pan-Cancer Study - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Myriad Genetics (MYGN) Reports Promising Results from MONSTAR-SCREEN 3 Study | MYGN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Breakthrough: Myriad Genetics New Cancer Test Detects Tumors 60% Better Than First-Gen Tests - Stock Titan

Jun 02, 2025
pulisher
May 29, 2025

Ameriprise Financial Inc. Has $2.88 Million Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World

May 29, 2025
pulisher
May 27, 2025

Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025 - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

Myriad Genetics Highlights New Research Advancements and Oncolog - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting | MYGN Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance

May 27, 2025
pulisher
May 27, 2025

Man Group plc Makes New $390,000 Investment in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World

May 27, 2025
pulisher
May 26, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect - ACCESS Newswire

May 26, 2025
pulisher
May 26, 2025

Deutsche Bank AG Purchases 27,541 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World

May 26, 2025
pulisher
May 25, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out - ACCESS Newswire

May 25, 2025
pulisher
May 25, 2025

Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud - ACCESS Newswire

May 25, 2025
pulisher
May 24, 2025

Trading (MYGN) With Integrated Risk Controls - news.stocktradersdaily.com

May 24, 2025
pulisher
May 23, 2025

ATTENTION MYGN Shareholders: Lost Money on Myriad Genetics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

May 23, 2025
pulisher
May 23, 2025

Scotiabank Downgrades Myriad Genetics (NASDAQ:MYGN) to Sector Perform - Defense World

May 23, 2025
pulisher
May 22, 2025

Microtomes Market Generated Opportunities, Future Scope - openPR.com

May 22, 2025
pulisher
May 22, 2025

Parp Inhibitor Biomarkers Market Generated Opportunities, - openPR.com

May 22, 2025
pulisher
May 22, 2025

BNP Paribas Financial Markets Purchases 23,408 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World

May 22, 2025
pulisher
May 22, 2025

Captrust Financial Advisors Grows Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World

May 22, 2025
pulisher
May 21, 2025

Myriad Genetics Shares Fall After Downgrade From Scotiabank - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 21, 2025
pulisher
May 21, 2025

Genetic Counseling Market Deep Research Report with Forecast by 2032 | Invitae Corporation, Myriad Genetics - openPR.com

May 21, 2025
pulisher
May 21, 2025

Myriad Genetics (MYGN) Faces Downgrade and Price Target Reduction | MYGN Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

This UnitedHealth Group Analyst Turns Bearish; Here Are Top 3 Downgrades For Wednesday - Benzinga

May 21, 2025
pulisher
May 21, 2025

Scotiabank Downgrades Myriad Genetics (MYGN) With Revised Price - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

May 21, 2025
pulisher
May 20, 2025

Scotiabank Downgrades Myriad Genetics (MYGN) Rating | MYGN Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect - ACCESS Newswire

May 20, 2025
pulisher
May 20, 2025

Myriad Genetics (MYGN) Faces Downgrade Amidst Challenging Quarte - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Myriad Genetics (MYGN) Faces Price Target Cut After Q1 Miss | MY - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Levi & Korsinsky Investigates Possible Securities Fraud by Myriad Genetics, Inc. (MYGN) - ACCESS Newswire

May 19, 2025
pulisher
May 19, 2025

Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp - Yahoo Finance

May 19, 2025

Myriad Genetics Inc Azioni (MYGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
diagnostics_research DGX
$174.34
price up icon 0.40%
diagnostics_research WAT
$351.17
price up icon 1.40%
diagnostics_research LH
$253.97
price up icon 0.72%
$163.76
price down icon 1.06%
diagnostics_research MTD
$1,184.34
price up icon 1.69%
diagnostics_research IQV
$152.32
price up icon 3.36%
Capitalizzazione:     |  Volume (24 ore):